| Dr Daniel David Lloyd, PSYD | |
|
2501 Oregon Pike, Lancaster, PA 17601-4890 | |
| (717) 735-1954 | |
| (717) 569-3045 |
| Full Name | Dr Daniel David Lloyd |
|---|---|
| Gender | Male |
| Speciality | Clinical Psychologist |
| Experience | 6 Years |
| Location | 2501 Oregon Pike, Lancaster, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043737208 | NPI | - | NPPES |
| PS018891 | Other | PA | STATE LICENSE - PSYD |
| 14561316 | Other | PA | CAQH |
| 103695101 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | PS018891 (Pennsylvania) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Philhaven | 8729991419 | 59 |
News Archive
A new report from Action on Hearing Loss has showed that there is a real demand for better technology solutions to help people with hearing loss overcome communication challenges when confronted by background noise.
"The United Nations' overall appeal to respond to the [Haiti cholera] epidemic, for $175 million, is 48 percent financed. Haiti's continuing health emergency may have been overlooked in a crush of world events, but while the sick and dying are waiting for the world to respond, the disease is not".
Kaiser Health News tracked a variety of stories over the weekend regarding the new federal health law and getting health coverage, including reports that Congress is poised to weigh changes in the health law's business purchase requirements and more coverage of young adults lacking health coverage Coverage (8/29). Read Saturday's and Sunday's news summaries.
BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.
› Verified 2 days ago
| Entity Name | Philhaven |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043316441 PECOS PAC ID: 8729991419 Enrollment ID: O20031110000103 |
News Archive
A new report from Action on Hearing Loss has showed that there is a real demand for better technology solutions to help people with hearing loss overcome communication challenges when confronted by background noise.
"The United Nations' overall appeal to respond to the [Haiti cholera] epidemic, for $175 million, is 48 percent financed. Haiti's continuing health emergency may have been overlooked in a crush of world events, but while the sick and dying are waiting for the world to respond, the disease is not".
Kaiser Health News tracked a variety of stories over the weekend regarding the new federal health law and getting health coverage, including reports that Congress is poised to weigh changes in the health law's business purchase requirements and more coverage of young adults lacking health coverage Coverage (8/29). Read Saturday's and Sunday's news summaries.
BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.
› Verified 2 days ago
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
A new report from Action on Hearing Loss has showed that there is a real demand for better technology solutions to help people with hearing loss overcome communication challenges when confronted by background noise.
"The United Nations' overall appeal to respond to the [Haiti cholera] epidemic, for $175 million, is 48 percent financed. Haiti's continuing health emergency may have been overlooked in a crush of world events, but while the sick and dying are waiting for the world to respond, the disease is not".
Kaiser Health News tracked a variety of stories over the weekend regarding the new federal health law and getting health coverage, including reports that Congress is poised to weigh changes in the health law's business purchase requirements and more coverage of young adults lacking health coverage Coverage (8/29). Read Saturday's and Sunday's news summaries.
BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel David Lloyd, PSYD 785 5th Ave Ste 3, Chambersburg, PA 17201-4232 Ph: (717) 263-9555 | Dr Daniel David Lloyd, PSYD 2501 Oregon Pike, Lancaster, PA 17601-4890 Ph: (717) 735-1954 |
News Archive
A new report from Action on Hearing Loss has showed that there is a real demand for better technology solutions to help people with hearing loss overcome communication challenges when confronted by background noise.
"The United Nations' overall appeal to respond to the [Haiti cholera] epidemic, for $175 million, is 48 percent financed. Haiti's continuing health emergency may have been overlooked in a crush of world events, but while the sick and dying are waiting for the world to respond, the disease is not".
Kaiser Health News tracked a variety of stories over the weekend regarding the new federal health law and getting health coverage, including reports that Congress is poised to weigh changes in the health law's business purchase requirements and more coverage of young adults lacking health coverage Coverage (8/29). Read Saturday's and Sunday's news summaries.
BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.
› Verified 2 days ago
Dr. Margaret J. Kay, ED.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2818 Lititz Pike, Lancaster, PA 17601 Phone: 717-569-6223 Fax: 717-560-9931 | |
Dr. Allison Lynn Bates, PH.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1755 Oregon Pike, Lancaster, PA 17601 Phone: 717-581-5255 Fax: 717-581-5259 | |
Simrit Kahlon, MS, PA-C Psychologist Medicare: Accepting Medicare Assignments Practice Location: 410 N Prince St, Lancaster, PA 17603 Phone: 717-560-7917 Fax: 717-560-6452 | |
Dr. Jonathan M. Gransee, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 313 W Liberty St Ste 113, Lancaster, PA 17603 Phone: 717-413-3130 Fax: 717-509-6734 | |
Dr. Kathleen Den Bleyker, PSY D Psychologist Medicare: Accepting Medicare Assignments Practice Location: 2461 Lititz Pike, Lancaster, PA 17601 Phone: 717-560-3525 Fax: 717-560-3995 | |
Dr. Ruth Benns-suter, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 2121 Oregon Pike Ste 201, Lancaster, PA 17601 Phone: 717-208-6599 Fax: 717-208-7753 |